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Abstract (word count = 241) 38 
Objectives: The aim of this study was to evaluate the long-term outcomes of the Norwood 39 
procedure with right ventricle-pulmonary artery (RV-PA) conduit for hypoplastic left heart complex 40 
(HLHC). 41 
Methods: A retrospective observational study was performed in 136 patients with HLHC who 42 
underwent a Norwood procedure with RV-PA conduit between 1998 and 2017. The probabilities 43 
of survival, reintervention and Fontan completion were analyzed.  44 
Results: Stage 1 survival was 91.9% (125/136). Reintervention for pulmonary artery stenosis 45 
was needed for 22% and 30% at stage 2 and 3, respectively, while 15% underwent reintervention 46 
for aortic arch recoarctation. Among 106 bidirectional Glenn survivors, 93 (68% of the total 47 
number of patients) had a Fontan completion, while four were not considered to be Fontan 48 
candidates. Risk factors for overall mortality included weighing <2.5 kg at the time of the Norwood 49 
procedure, intact atrium septum, total anomalous pulmonary vein connection, and more than mild 50 
atrioventricular regurgitation at the time of the Norwood procedure. Overall survival was 80.9%, 51 
72.3% and 62.8% at 1, 5, and 20 years, respectively.  52 
Conclusions: Probabilities of survival and Fontan completion were acceptable under the current 53 
surgical strategy incorporating RV-PA Norwood procedure as the first palliation. Incorporating a 54 
strategy to maintain pulmonary artery growth and ventricular function through the staged repair is 55 
of prime importance. Further studies are necessary to observe changes in atrioventricular 56 
regurgitation as well as in right ventricular function, in patients who require atrioventricular valve 57 
interventions during the staged Fontan completion.  58 
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INTRODUCTION 80 
Hypoplastic left heart syndrome (HLHS) is characterized by undeveloped left-sided heart 81 
structures that are insufficient to sustain systemic circulation (1). Norwood stage palliation greatly 82 
improved the outcomes of patients with HLHS; however, performing the Norwood procedure with 83 
a modified Blalock-Taussig shunt (BTS) is technically challenging and still carries significant 84 
mortality and morbidity (2). Despite successful reconstructive surgery, death often occurs in the 85 
first 24 to 48 hours after surgery due to hemodynamic instability secondary to the unpredictable 86 
rapid fall in pulmonary vascular resistance (3).  87 
The introduction of right ventricle-pulmonary artery (RV-PA) conduit as an alternative to modified 88 
BTS resulted in an unprecedented excellent early survival after the Norwood procedure. The 89 
resultant high diastolic pressure (i.e., high coronary artery pressure), lower aortic saturation, and 90 
a decreased volume work improved myocardial perfusion and ventricular function (4,5). 91 
Computational modeling analyses have shown that hemodynamic performance after Norwood 92 
procedure with an RV-PA conduit is more effective than after the procedure with a modified BTS 93 
(6). 94 
 We have previously reported early survival results after Norwood stage 1 palliation (7). In this 95 
study, we sought to see both short and long-term results, including probabilities of survival and 96 
reintervention after the Norwood procedure, as well as completion of the Fontan operation at our 97 
institution. 98 
 99 
MATERIALS AND METHODS 100 
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A single-center retrospective observational study was performed using the medical records of 136 101 
patients with HLHS or HLHS variants who underwent a modified Norwood procedure using the 102 
RV-PA conduit at Okayama University Hospital between January 1998 and December 2017. This 103 
retrospective observational study was approved by the institutional review board on March 31, 104 
2019, and the requirement to obtain informed consent was waived. High-risk patients for the 105 
primary Norwood procedure met the following criteria: 1) gestational age, <37 weeks, 2) body 106 
weight, <2.5 kg at birth, 3) more than moderate atrioventricular valve regurgitation (AVVR), 4) 107 
organ failure, or 5) cerebral hemorrhage. Some, but not all of these patients received bilateral 108 
pulmonary artery banding (Bil.PAB) prior to the Norwood procedure. Six patients subsequently 109 
underwent Norwood and bidirectional Glenn (BDG) procedures and all survived. These six 110 
patients were excluded as no RV-PA conduit was used.  111 
The medical and operative records, and angiographic and echocardiographic data for all patients 112 
were reviewed. Anatomic diagnosis was based on a review of echocardiography and operative 113 
findings. Follow-up status was determined by reviewing medical records and through contacts 114 
with the referring cardiologists.  115 
 116 
Surgical technique 117 
Details on the operative procedures used in this study have been reported previously (5,7). 118 
Briefly, the following technical modifications for the RV-PA conduit were performed: for patients 119 
weighing up to 3.5 kg, a 5-mm expanded polytetrafluoroethylene (ePTFE) ringed conduit was 120 
used. Autologous pericardium was initially used in 10 patients to patch the distal main PA; 121 
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however, this was changed to cuffed ePTFE tubes due to early obstruction of the main PA. 122 
Initially, a right ventriculotomy at the outlet portion was made using a knife; however, this was 123 
changed to a coronary puncher to create a consistent small hole. 124 
 125 
Statistical analysis  126 
Continuous variables were reported as the median (interquartile range) for skewed data, or the 127 
mean (standard deviation) for normally distributed values, while categorical variables were 128 
reported as absolute frequency (percentage). Continuous variables were compared using 129 
Student’s t -test or Mann-Whitney U test, based on the normality of the data. Categorical variables 130 
were compared using Fisher’s exact test or chi-square test. Survival was assessed using Kaplan-131 
Meier analysis, and differences between groups were analyzed using the log-rank test. 132 
Competing risk outcomes were analyzed with a cumulative incidence function. Exclusive 133 
endpoints were death, Fontan completion, and the remaining patients being alive without Fontan 134 
completion. As a result, we used a non-parametric method to estimate the cumulative incidence 135 
function from a specific cause over time using the %CIF macro in SAS. 136 
Risk factors for time-related outcomes were tested using Cox regression analysis. Univariate 137 
analysis identified variables with a P value <0.10, and these were then entered into a multivariate 138 
Cox proportional hazards regression model in a stepwise fashion to determine the independent 139 
predictors of outcomes. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported 140 
for significant multivariate risk factors. The level of statistical significance was set at P <0.05. All 141 




Patients’ characteristics 145 
Patients’ characteristics are shown in Table 1. A total of 109 patients had classical HLHS, and the 146 
remaining 27 had variants of HLHS with left ventricular and aortic arch hypoplasia, consisting of 147 
the following diagnoses: double-outlet right ventricle with systemic outlet obstruction (n = 8), 148 
ventricular septal defect with critical aortic stenosis, coarctation of the aorta, or interrupted aortic 149 
arch (n = 16) and heterotaxy syndrome (n = 3). Intact atrium septum (IAS) was associated with 150 
six patients (4%). During the study period, 30 patients with high-risk status received Bil.PAB as 151 
the first palliation.  152 
 Median age at the time of Norwood procedure was nine (range: 4–25) days, and median weight 153 
was 3.0 (range: 2.6–3.2) kg. Twenty-six patients (18%) weighed less than 2.5 kg. Ten patients 154 
(7%) were premature (gestational age <37 weeks). More than mild AVVR was associated with 27 155 
patients (20%), and RV dysfunction (defined as less than 50% of RV ejection fraction [RVEF]) 156 
was associated with four patients (3%). Mean lower body arrest, mean myocardial ischemic, and 157 
mean cardiopulmonary bypass time were 55 ± 18 minutes, 57 ± 20 minutes, and 148 ± 36 minutes, 158 
respectively. 159 
 160 
Operative mortality of Norwood procedure 161 
Stage 1 survival was 91.9%. Operative mortality, defined as death within 30 days if discharged or 162 
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no time limit if remaining in the hospital, occurred in 11 patients (8%). Causes of death included 163 
sudden death (n = 3), heart failure (n = 3), desaturation due to pulmonary hypertension (n = 2), 164 
septic shock (n = 2), and tamponade (n = 1). Body weight <2.5 kg, mitral atresia/aortic stenosis, 165 
IAS, total anomalous pulmonary vein connection (TAPVC), and RV dysfunction affected operative 166 
mortality, while preceding Bil.PAB did not affect operative mortality (P = 0.71) (Table 1). 167 
 168 
Follow-up 169 
Clinical outcomes for all patients are summarized in Figure 1. Mean follow-up duration was 109 170 
± 78 months. There were eight late deaths after the Norwood procedure. These occurred due to 171 
desaturation caused by shunt obstruction (n = 4), sudden death (n = 2), suffocation caused by 172 
milk aspiration (n = 1), or respiratory syncytial viral bronchiolitis (n = 1). Among stage 1 survivors 173 
(n = 117), four patients received an additional systemic-pulmonary artery shunt followed by 174 
biventricular repair. The BDG procedure was performed in 110 patients. Four patients died in the 175 
hospital from heart failure (n = 1), heparin-induced thrombocytopenia (n = 1), BDG obstruction (n 176 
= 1), or mediastinitis (n = 1). There were nine late deaths after BDG procedure due to heart failure 177 
(n = 5), septic shock (n = 2), or pneumonia (n = 1). One patient required take-down of BDG 178 
circulation due to central venous high pressure and eventually died from heart failure. Four 179 
patients could not achieve Fontan completion; reasons for this failure are listed in Table 3. 180 
Therefore, 87 patients underwent a total cavopulmonary connection (TCPC) procedure. One 181 
patient died in the hospital due to intracranial bleeding. Eleven late deaths occurred after the 182 
TCPC procedure due to heart failure (n = 7), rupture of the esophageal varices (n = 2), thrombosis 183 




Surgical intervention for recoarctation of the neo-aortic arch was required in 17 patients (15%) at 187 
stage 2, and 5 patients (6%) at stage 3. Atrioventricular valve plasty was performed in 17 patients 188 
(15%) at stage 2, and 21 patients (24%) at stage 3, including valve replacement with a mechanical 189 
valve (n = 1). Catheter intervention for recoarctation of the neo-aortic arch was required in 19 190 
patients (17%) at stage 2, and 7 patients (8%) at stage 3. 191 
192 
PA growth and ventricular function 193 
Cardiac catheterization was performed before the BDG (n = 117) and TCPC (n = 103) procedures 194 
(Table 2). After BDG, the RVEF decreased significantly from 66 (range: 60–73) to 57 (range: 52–195 
63) percent, P <0.001; however, right ventricular end-diastolic pressure (RVEDP) did not change196 
significantly. Before the BDG procedure, 26 (22%) patients developed pulmonary artery stenosis 197 
(PS), while 33 (30%) patients developed PS before the TCPC procedure. The PA index did not 198 
differ between stage 2 and stage 3 (208 [range: 163–261] vs. 215 [range: 173–253] mm2/m2, P = 199 
0.58). 200 
201 
Failing to achieve Fontan completion  202 
Among 106 stage 2 survivors, four patients failed to achieve Fontan completion. The patients’ 203 
courses are summarized in Table 3. All patients had both RV dysfunction and severe hypoplastic 204 
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PA. Patient 1 had preserved RV function with trivial AVVR; however, she suffered severe left PS 205 
after stage 1, and her PA did not grow despite a left PA plasty. Furthermore, an advanced 206 
atrioventricular block caused dyssynchrony of the RV, which deteriorated the RV function. Patient 207 
2 had moderate AVVR before the BDG procedure and underwent tricuspid valve plasty (TVP) at 208 
the time of the BDG procedure. However, the remaining moderate AVVR caused a low ejection 209 
fraction (EF) and high RVEDP, eventually causing poor pulmonary artery index (PAI) values. 210 
Patient 3 had cerebral palsy after stage 1 due to hemodynamic instability, which required 211 
emergency resuscitation. He also underwent TVP at stage 2, but moderate AVVR remained. 212 
Furthermore, he suffered severe left PA stenosis, causing hypoplastic PA. Patient 4 not only had 213 
moderate AVVR before stage 2, but also had pulmonary high flow status. Before stage 3, her RV 214 
function deteriorated, followed by poor PAI values due to high RVEDP. 215 
 216 
Risk analysis of overall mortality and long-term outcomes 217 
Multivariate analysis indicated that risk factors for overall mortality included body weight <2.5 kg 218 
at the time of the Norwood procedure (HR 3.02; 95% CI: 1.49–6.15, P <0.001), IAS (HR 6.70; 219 
95% CI: 2.63–17.1, P <0.001), TAPVC (HR 4.88; 95% CI: 1.44–16.6, P = 0.011), and more than 220 
mild AVVR (HR 2.85; 95% CI: 1.51–5.38, P <0.001) (Table 4). Overall survival was 80.9%, 72.3%, 221 
and 62.8%, and the probability of Fontan completion was 6.6%, 45.6%, and 64.0% at 1, 5, and 222 
20 years, respectively (Figure 2A). 223 
 Survival was stratified by the presence or absence of AVVR at the time of Norwood procedure. 224 
Survival was higher in patients with equal or less than trivial AVVR than in those with more than 225 
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mild AVVR. Overall survival in equal or less than trivial AVVR patients was 88.9%, 76.2%, and 226 
70.3% at 1, 5 and 20 years, respectively, vs 55.6%, 32.0%, and 32.0% in patients with more than 227 
mild AVVR (P <0.001; Figure 2B). 228 
229 
DISCUSSION 230 
In our 20-year experience with using the RV-PA conduit in Norwood stage 1 palliation, stage 1 231 
survival was 92%, which was the same as the survival reported 10 years ago (7). These positive 232 
results are due to the introduction of RV-PA conduit, various surgical techniques and thoughtful 233 
perioperative care. Although questions about the appropriate systemic-pulmonary shunt and risk 234 
factors for Norwood stage 1 mortality have been debated, long-term experience at a single-235 
institution have rarely been reported. 236 
 We analyzed the factors affecting operative mortality at stage 1 and variations in PA conditions 237 
and ventricular function to understand long-term problems, particularly the failure to achieve 238 
Fontan completion, and overall mortality. In our study, low weight at the time of surgery, IAS, 239 
TAPVC, and RV dysfunction were found to be risk factors at stage 1. Despite often requiring a 240 
reintervention for PS, adequate PA growth was obtained in most of the patients. Patients who did 241 
not achieve Fontan completion had reduced PA index and RV dysfunction. More than mild AVVR 242 
at the time of the Norwood procedure gradually exacerbated RV function as a systemic chamber, 243 
leading to long-term mortality.  244 
245 
Operative mortality of Norwood procedure 246 
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As many studies have reported (7-9), low weight at surgery, IAS, TAPVC, and RV dysfunction are 247 
risk factors affecting operative mortality after the Norwood procedure. Our strategy for high-risk 248 
patients is to perform a Bil.PAB procedure prior to the Norwood procedure to observe pulmonary 249 
function. Since preceding Bil.PAB did not affect operative mortality, our strategy to perform rapid 250 
two-stage (i.e., Bil.PAB following Norwood procedure in approximately one month) appears to be 251 
reasonable for patients with a low body weight and gestational age.  252 
253 
PA growth and ventricular function 254 
The size of the PA is an important factor for an optimal passive pulmonary perfusion in Fontan 255 
circulation (10). In fact, four patients in our study were not able to achieve Fontan completion due 256 
to having a small PA. The absence of a pulmonary pumping chamber for active blood supply to 257 
the lungs in HLHS patients results in a low-pulsatile flow into the pulmonary arteries and 258 
underfilling of the pulmonary vascular bed (11). Therefore, 20% of our patients at each stage 259 
underwent PA plasty for morphologic PS which led to high pulmonary artery pressure and a small 260 
PA. Because of the “parallel” circulation with a systemic-pulmonary shunt, the preload for the RV 261 
is large compared to the “in-series” circulation after a BDG procedure, which reflects hyperkinetic 262 
RV before BDG. Therefore, BDG should be performed around six months of age to preserve 263 
ventricular function. 264 
265 
Anatomic and physiologic uniqueness of HLHS 266 
In our institution, management of HLHS patients has had a goal of restricting the pulmonary blood 267 
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flow to preserve ventricular function, while partially clipping the RV-PA conduit at the time of 268 
cessation of cardiopulmonary bypass or a delayed sternal closure. Reduced pulmonary blood 269 
flow/systemic blood flow (Qp/Qs) was also able to preserve tricuspid valve function. Although 270 
Qp/Qs was not evaluated in this study, the fact that RVEDP in HLHS patients did not differ 271 
reflected the difference of Qp management. RV function in HLHS patients might deteriorate not 272 
only from regurgitation of the tricuspid valve caused by high Qp/Qs as the atrioventricular valve 273 
of the systemic chamber, but also by a recoarctation of the aortic arch. A propensity score-274 
matched, multi-institutional large cohort study was performed by the Congenital Heart Surgeons’ 275 
Society (12), in which the authors found that late RV dysfunction and late tricuspid regurgitation 276 
(TR) were not different between an RV-PA group and a BTS group. 277 
Another concern for HLHS patients is PA growth. In this study, PA plasty as a concomitant 278 
procedure was required frequency. In addition to the management of low Qp/Qs, a high incidence 279 
of morphologic PS might be related to low PAI. In most cases, a retracted main PA by RV-PA 280 
conduit was confirmed by computed tomography, according to the body growth and RV. PA 281 
hypoplasia and stenosis are well-recognized complications after the Norwood procedure (13). 282 
Honjo et al. reported that a preventive patch plasty of the branch PA was performed in the vast 283 
majority of the patients at stage 2, as it is widely accepted that PA growth is not obtained after 284 
BDG (14, 15).  285 
286 
Overall mortality and its risk factors 287 
Unlike other factors as IAS, TAPVC, RV dysfunction, and low weight at the time of the Norwood 288 
17 
procedure, more than mild AVVR at the time of the Norwood procedure was identified as a sole 289 
risk factor for overall mortality. Figure 2B shows the stepwise decline of overall survival even after 290 
the Fontan completion in patients with more than mild AVVR. Most of these patients died of heart 291 
failure. This finding indicates that a failing RV in systemic circulation that is gradually exacerbated 292 
by AVVR is not compatible with lifelong health. Some may suggest that heart transplantation is 293 
the best choice for these patients; however, this is not a realistic management option in our country. 294 
Alsoufi et al. described that annular dilatation was an important component of TR in all patients, 295 
and a fair number of those patients (14/30) had associated structural anomalies (16). An 296 
association with structural anomalies is expected to continue to have a significant regurgitation 297 
despite repetitive TVP (16, 17). Subsequently, residual TR continues to deteriorate RV function, 298 
which is reported as one of the two determinants of late outcomes following the Fontan procedure, 299 
and is related to longevity of TV competence (12, 17, 18). 300 
301 
LIMITATION 302 
The current report had the typical limitations of a retrospective observational study. Specifically, 303 
changes in perioperative management during the study period may have affected our results. In 304 
addition, the rarity of this disease meant we had a small cohort size, and the multiple variables 305 
described in this study were a consequence of different surgical approaches. 306 
307 
CONCLUSION 308 
Application of the RV-PA conduit yielded early excellent results, as well as high probability of 309 
18 
achieving Fontan completion and long-term survival. Incorporating a strategy to maintain these 310 
factors through staged repair is important. TR had a negative impact on overall survival. Therefore, 311 
future studies to measure changes in TR as well as in RV function are necessary in those requiring 312 
intervention on TV during the staged Fontan completion. 313 
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FIGURE LEGENDS 319 
320 
Figure 1. The current status of all hypoplastic left heart syndrome or variant patients. 321 
322 
 Figure 2. (A) Competing risk analysis of clinical outcomes, (B) Kaplan-Meier analysis for 323 







Table 1. Demographics (n = 136) and Factors Associated with Operative Mortality of Norwood 
Procedure 








Male gender 76 (56) 69 (55) 7 (64) 0.59 
Age at NW (days) 9 (4–25) 7 (4–26) 12 (6–24) 0.90 













Weight at NW <2.5 kg 26 (18) 20 (16) 6 (54) 0.002 
Premature birth 10 (7) 8 (6) 2 (18) 0.15 
Genetic or extracardiac anomalies 16 (12) 15 (12) 1 (9) 0.77 
HLHS subtype 
  MA/AA 54 (40) 53 (42) 1 (9) 0.030 
  MA/AS 7 (5) 4 (3) 3 (27) 0.001 
21 
  MS/AA 30 (22) 26 (21) 4 (36) 0.23 
  MS/AS 18 (13) 17 (14) 1 (9) 0.67 





(80) 9 (81) 0.88 
Associated anomaly 
  Intact atrium septum 6 (4) 4 (3) 2 (18) 0.020 
  TAPVC 4 (3) 2 (2) 2 (18) 0.002 
Right ventricular dysfunction 4 (3) 2 (2) 2 (18) 0.002 
Atrioventricular regurgitation >- mild 27 (20) 23 (18) 4 (36) 0.16 
Ascending aorta diameter < 2.0 mm 12 (9) 9 (7) 3 (27) 0.024 
preceding Bil.PAB 30 (22) 27 (22) 3 (27) 0.71 







Myocardial ischemia time (min) 57 ±20 57 ±20 60 ±21 0.64 
Lower body arrest time (min) 55 ±18 55 ±17 56 ±24 0.77 
Data presented as median (interquartile range) or n (%) or mean (±SD). NW, Norwood; 
22 
HLHS, hypoplastic left heart syndrome; AA, aortic atresia; AS, aortic stenosis; MA, mitral 
atresia; MS, mitral stenosis; TAPVC, total anomalous pulmonary vein connection; Bil.PAB, 




Table 2. Evaluation of PA Growth and Cardiac Function in HLHS Patients 
Variables before BDG (n = 
117) 




  RVEF (%) 66 (60–72) 57 (52–63) <0.001 
  RVEDP (mmHg) 7 (6–7) 6 (5–7) 0.92 
  PA index (mm2/m2) 208 (163–262) 215 (173–253) 0.58 
  Right PA pressure (mmHg) 12 (11–14) 11 (9–13) <0.001 
  Left PA pressure (mmHg) 13 (12–15) 11 (9–13) <0.001 
  PA resistance (W/U) 1.7 (1.2–2.0) 1.6 (0.9–2.0) 0.55 
  Morphologic PS 26 (22) 33 (30) 0.101 
Data presented as median (interquartile range) or n (%). PA, pulmonary artery; HLHS, 
hypoplastic left heart syndrome; BDG, bidirectional Glenn; TCPC, total cavopulmonary 
connection; RVEF, right ventricular ejection fraction; RVEDP, right ventricular end-diastolic 
pressure; PS, pulmonary artery stenosis. 
332 
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Table 3. Summary for patients who are not Fontan candidates 
Patient subtype preceding 
Bil.PAB 
Weight  
at NW (kg) 
Age   







1 MA/AA yes 2.9 61 trivial no mild 
2 MA/AA yes 3.2 62 mild yes moderate 
3 MS/AA yes 2.8 121 trivial yes moderate 
4 MS/AA no 3.2 7 mild yes moderate 
Bil.PAB, bilateral pulmonary artery banding; NW, norwood; AVVR, atrioventricular valve 
regurgitation; AVVP, atrioventricular valvuloplasty; EF, ejection fraction; EDP, end-diastolic 
pressure; PAP, pulmonary artery pressure; PAI, pulmonary artery index; Qp/Qs, pulmonary 
blood flow/systemic blood flow ratio; PS, pulmonary artery stenosis; AA, aortic atresia; AS, aortic 
stenosis; MA, mitral atresia; MS, mitral stenosis; BDG, bidirectional Glenn; PA, pulmonary artery; 
RV, right ventricle; TVP, tricuspid valve plasty   
333 
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(mm2/m2) Qp/Qs PS 
Reason of Fontan 
not achieved 
43 10 16 113 0.55 yes 
RV dysfunction 
+ hypoplastic PA
56 11 12 95 0.87 no 
RV dysfunction 
+ hypoplastic PA
54 12 15 105 0.74 yes 
RV dysfunction 
+ hypoplastic PA






Table 4. Univariate and Multivariate Analysis of Risk factors For Overall Mortality (n = 136) 
Characteristics Survivors (n = 
92) 
Mortality (n = 
44) 
P value HR (95% CI); P value 
(Univariate) (Multivariate) 
Male gender 50 (54) 26 (59) 0.60 
Age at NW (days) 8 (4–36) 9 (4–18) 0.47 







Weight at NW <2.5 kg 9 (10) 17 (38) <0.001 3.02 (1.49–6.15); P = 0.002* 
Premature birth 3 (3) 7 (15) 0.008 1.20 (0.41–3.53); P = 0.74 
Genetic or extracardiac anomalies 13 (14) 3 (6) 0.22 
HLHS subtype 
27 
  MA/AA 41 (45) 13 (29) 0.094 0.60 (0.30–1.20); P = 0.14 
  MA/AS 3 (3) 4 (9) 0.15 
  MS/AA 18 (20) 12 (27) 0.31 
  MS/AS 12 (13) 6 (13) 0.92 
  HLHS variants 18 (20) 9 (20) 0.90 
Associated anomaly 
  Intact atrium septum 0 (0) 6 (100) <0.001 6.70 (2.63–17.1); P <0.001* 
  TAPVC 1 (1) 3 (6) 0.06 4.88 (1.44–16.6); P = 0.011* 
Right ventricular dysfunction 0 (0) 4 (9) 0.003 3.09 (0.70–13.0); P = 0.13 
Atrioventricular regurgitation >- mild 11 (12) 16 (36) 0.001 2.85 (1.51–5.38); P <0.001* 
Ascending aorta diameter <2.0 mm 6 (7) 6 (13) 0.13 
preceding Bil.PAB 25 (27) 6 (13) 0.078 0.72 (0.28–1.86); P = 0.50 
28 
Data presented as median (interquartile range) or n (%). HR, hazard ratio; CI, confidence interval; NW, Norwood; HLHS, 
hypoplastic left heart syndrome; AA, aortic atresia; AS, aortic stenosis; MA, mitral atresia; MS, mitral stenosis; TAPVC, total 
anomalous pulmonary vein return; Bil.PAB, bilateral pulmonary artery banding   
Only variables having a P value <0.10 in the univariable analysis are entered into the multivariable Cox regression model   
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BDG completion +BVR = 86.0%
(117/136)
Fontan completion = 68.3%
(93/136)





















































































0    5     0     15     20  25
Years from Norwood
Number at Risk:
109  75  52  25  6
27  13  7 5  2
P < 0.001
Figure2B
